Description_x000D_ General description_x000D_ Diazoxide is a nondiuretic benzothiadiazine, which is used for the treatment of hypoglycemia, von Gierke′s disease, acute and malignant hypertension. It acts as a beta cell KATP channel opener. Diazoxide prevents the secretion of insulin._x000D_ Application_x000D_ Diazoxide has been used for diazoxide infusion. It has also been used to prevent depolarization for K+-induced exocytosis._x000D_ Biochem/physiol Actions_x000D_ Selective ATP-sensitive K+ channel activator in both vascular smooth muscle and pancreatic β-cells; antihypertensive._x000D_ Features and Benefits_x000D_ This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more._x000D_ This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here._x000D_ This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here._x000D_ Legal Information_x000D_ LOPAC is a registered trademark of Sigma-Aldrich Co. LLC